Stereotactic body radiation therapy for primary liver tumors with adverse factors

• 作者: Takuya Shimizuguchi Jun Imamura Simpei Hashimoto Katsuyuki Karasawa
• 来源期刊: 肝癌研究（英文版）
• 年，卷（期）: 2020,（10）
• 所属期刊栏目: Original Article
• 页码范围: 1-10
• 页数: 10页
• 语种: 英文
• DOI: 10.20517/2394-5079.2020.51

摘要

Aim: To test the efficacy and safety of liver stereotactic body radiation therapy (SBRT) in patients who harbor adverse factors. Methods: We retrospectively evaluated the outcomes of liver SBRT in a single cancer center. We invented criteria consisting of two physical factors and two tumor factors to measure the treatment difficulty in each case. The clinical outcomes and toxicity were evaluated by stratification of the harboring factors. Results: A total of 24 (23 hepatocellular carcinoma and 1 intrahepatic cholangiocarcinoma) patients were eligible for this study, with a median follow-up duration of 18 months. Of all eligible patients, 21 patients (88％) had one or more factors. The local control, progression-free survival, and overall survival rates for all patients at 2 years were 89％, 42％, and 76％ respectively. In the patients with physical and tumor adverse factors, local control/progression-free survival/overall survival rates at 2 years were 100％/42％/69％ and 80％/23％/78％, respectively. The subgroup of 11 patients with 2 or more factors showed comparable local control rate at 2 years to the subgroup of 13 patients with 0 to 1 factors (100％ vs. 86％, P = 0.59). One patient (4.2％) experienced a decline in the Child-Pugh score by 2 points at 3 months after the treatment. Grade 2 to 3 gastrointestinal toxicity was observed in three patients. Conclusion: SBRT showed a high local control rate with acceptable toxicity for the group of liver cancer patients harboring both physical and tumor adverse factors as long as conducted following patient selection and dose constraints that were used in this study.